Innovative phage lysin HY-133 enters phase I clinical study
HYpharm’s innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against Staphylococcus aureus including multi-resistant strains and is intended to combat its colonisation in the nose.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.
